J&J Appeals To Discard $2.5 M Risperdal Verdict
J&J Appeals To Discard $2.5 M Risperdal Verdict

Introduction
Risperdal manufacturer, Johnson & Johnson's unit, requested a Pennsylvania appeals court to discard a $2.5 million verdict against them. J&J asserted that the trial judge prevented the use of a scientific article to challenge an expert's opinion that Risperdal use leads to abnormal breast growth in young boys.
The verdict in question was the second-largest against Risperdal makers awarded to the plaintiff in February 2015. The plaintiff consumed the drug for a period of five years to treat autism-related behavioral issues. His parents claimed his abnormal breast growth was the result of Risperdal consumption.
Over 7,000 Risperdal product liability lawsuits against J&J are filed in the Pennsylvania State Court. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
Latest News
First Federal Bellwether Trial Set in Strattice Mesh Case
Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…
Tepezza Hearing Loss Trial Set for June 2026
The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.
This decision comes as attorneys…